Promising Phase III Data For Roche/Ipsen's Taspoglutide Heats Up GLP-1 Race
This article was originally published in The Pink Sheet Daily
Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide.
You may also be interested in...
Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.
Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.